Veradermics, Incorporated (MANE) Stock Price & How to Invest
Last updated July 2026
Short answer
MANE is Veradermics, a late-stage dermatology biopharma whose lead asset is VDPHL01, an oral extended-release version of minoxidil for pattern hair loss, so investing in it means buying a pre-revenue, single-asset clinical story rather than a profitable business.
MANE stock price
As of 2026-07-16, Veradermics, Incorporated (MANE) last closed at $105.83, up 16.4% over the past month. Over its trading history so far it has traded between $37.03 and $129.74.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Veradermics, Incorporated's investor relations page. Walnut is informational, not investment advice.
What does Veradermics, Incorporated (MANE) do?
Veradermics, Inc. (NYSE: MANE) is a New Haven, Connecticut biopharmaceutical company founded in 2019 and focused on dermatology and aesthetics. Its lead candidate, VDPHL01, is a proprietary oral, extended-release formulation of minoxidil designed to boost hair regrowth while limiting the cardiac exposure associated with existing oral minoxidil use. The company has completed enrollment in a roughly 519-patient Phase 2/3 study for male pattern hair loss that showed statistically significant hair-count gains versus placebo, and has additional pivotal work underway. A smaller pipeline includes VDMN (a dissolvable microarray patch for common warts), VDAA (alopecia areata), and VDMC (molluscum contagiosum).
The investment picture is defined by the fact that Veradermics has no approved product and effectively no product revenue. After a February 2026 IPO at $17 and a follow-on plus private placement in April 2026, the company raised roughly $766 million in aggregate during 2026, giving it a substantial cash cushion to fund trials. The stock has been extraordinarily volatile, trading in a wide range and carrying a multibillion-dollar market value entirely on clinical expectations. As with any pre-revenue biotech, the range of outcomes is very wide, and the eventual result depends on trial data, FDA decisions, commercial execution, and competition.
What's driving Veradermics, Incorporated (MANE)?
1. Large, underserved hair-loss market
Pattern hair loss affects a very large population, and existing options are dominated by decades-old generics (topical minoxidil, oral finasteride) and cash-pay telehealth. An oral minoxidil pill with a cleaner tolerability profile and pivotal data could address demand that current products only partly satisfy.
2. Statistically significant lead-asset data
VDPHL01 has shown statistically significant hair-count increases over placebo in its Phase 2/3 male pattern hair loss study, with reported gains on the order of 30 or more hairs per square centimeter. Positive pivotal readouts are the single biggest potential value driver for the company.
3. Well-funded balance sheet
Roughly $766 million raised in 2026 across the IPO, a follow-on, and a private placement leaves Veradermics with a sizable cash position (about $391 million reported at March 31, 2026, before the later raise). That runway reduces near-term financing pressure while the pivotal program advances.
4. Pipeline optionality beyond hair loss
Programs in warts, alopecia areata, and molluscum contagiosum give the company additional dermatology shots on goal. These are earlier and smaller than VDPHL01, but they broaden the story beyond a single indication if the lead asset progresses.
What are the risks to Veradermics, Incorporated (MANE)?
Veradermics is pre-revenue and has no approved product, so it generates ongoing net losses (about $99 million on a trailing basis) and depends on clinical and regulatory success it has not yet achieved. The valuation, a multibillion-dollar market cap on essentially zero revenue, leaves little room for disappointment, and the shares have been extremely volatile since the IPO. Value is concentrated in VDPHL01, meaning a failed pivotal trial, a safety signal, or an FDA setback could sharply impair the company. Even with approval, it would compete against cheap generic minoxidil and finasteride and against telehealth platforms like Hims & Hers, Keeps, and Ro. Future capital raises could dilute existing shareholders.
How is Veradermics, Incorporated (MANE) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Veradermics, Incorporated's investor relations page or your broker.
- Revenue (TTM): ~$0 (pre-commercial)
- Net loss (TTM): ~$99M
- EPS (TTM): ~-$15.84
- Cash & securities: ~$391M at Mar 31, 2026 (pre later raise)
- Market cap: ~$4.4B
- Shares outstanding: ~42M
Traditional valuation multiples do not apply because Veradermics has no product revenue and posts consistent losses. The market value reflects expectations for VDPHL01 rather than current financials. The stock has swung across a wide 52-week range (roughly $32 to $131) since its February 2026 IPO at $17.
Who competes with Veradermics, Incorporated (MANE)?
Hair-loss telehealth and consumer brands
Hims & Hers, Keeps, and Ro sell existing minoxidil and finasteride regimens directly to consumers. They already reach the same patients Veradermics would target and set the price and convenience bar for any new hair-loss therapy.
Generic and legacy dermatology drugs
Topical minoxidil and oral finasteride are inexpensive, widely available generics that are the standard of care. VDPHL01 would need to demonstrate meaningfully better efficacy, tolerability, or convenience to justify a branded price against them.
Clinical-stage dermatology biopharma
Other dermatology-focused developers pursuing hair loss, alopecia areata, and related conditions compete for trial patients, physician attention, and investor capital. Their data and approvals could reshape the competitive landscape Veradermics enters.
How to invest in Veradermics, Incorporated (MANE)
There are three common ways to get MANE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so MANE sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where MANE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Veradermics, Incorporated (MANE)
MANE is a richly valued, pre-commercial biotech whose value hinges almost entirely on whether VDPHL01 reaches the market, which makes it a high-volatility, binary-outcome holding.
More on Veradermics, Incorporated (MANE)
Whether MANE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MANE a buy?, and where the stock could go from here in the MANE stock forecast.
For income investors, whether MANE pays a dividend and how the payout looks is covered in does MANE pay a dividend?
Build a basket around MANE with Walnut
Use Veradermics, Incorporated as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What company is MANE stock?
+
MANE is the NYSE ticker for Veradermics, Inc., a late-stage dermatology biopharmaceutical company based in New Haven, Connecticut. It develops treatments for hair loss and other skin conditions and went public in February 2026.
What is Veradermics' main product?
+
Its lead candidate is VDPHL01, an oral, extended-release formulation of minoxidil aimed at pattern hair loss. It is designed to improve hair regrowth while reducing the cardiac exposure linked to conventional oral minoxidil, and it is in pivotal-stage testing.
Does Veradermics make any money?
+
No. As of July 2026 Veradermics is pre-commercial with essentially no product revenue and a trailing net loss of roughly $99 million. Like most clinical-stage biotechs, it funds operations from capital raised rather than sales.
Why has MANE stock been so volatile?
+
The shares priced at $17 in the February 2026 IPO and later traded many times higher, moving through a wide range. Pre-revenue biotech valuations swing sharply on trial data, analyst views, and sentiment, since there are no earnings to anchor the price.
Is VDPHL01 approved by the FDA?
+
No. As of July 2026 VDPHL01 is investigational and not FDA approved. It has shown statistically significant results versus placebo in a Phase 2/3 hair-loss study, but it must still complete pivotal trials and regulatory review before any potential approval.
How much cash does Veradermics have?
+
The company reported about $391 million in cash and marketable securities as of March 31, 2026, and raised roughly $766 million in aggregate across its 2026 IPO, follow-on, and private placement, giving it a substantial runway to fund clinical development.
Who competes with Veradermics?
+
In hair loss it faces cheap generic minoxidil and finasteride, telehealth brands like Hims & Hers, Keeps, and Ro, and other clinical-stage dermatology developers. Any new therapy would have to outperform low-cost, widely available options to gain traction.
What are the biggest risks with MANE?
+
The main risks are its lack of any approved product, dependence on VDPHL01, ongoing losses, a very high valuation relative to zero revenue, extreme share-price volatility, competition from generics and telehealth, and the potential for dilution from future capital raises.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Veradermics, Incorporated's investor relations page or your broker before making investment decisions.